CONTRAVE®
January 2, 2025
Press Releases
CURRAX PHARMACEUTICALS
September 24, 2024
Currax Pharmaceuticals Unveils New Disease Awareness Campaign to “Quiet the Food Noise,” a Key Barrier for Individuals Seeking Weight Loss
See moreCONTRAVE®/MYSIMBA®
August 27, 2024
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study
See moreCONTRAVE®/MYSIMBA®
July 24, 2024
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues
See moreCURRAX PHARMACEUTICALS
January 25, 2024
Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial
See moreCONTRAVE®/MYSIMBA®
October 19, 2023
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study
See moreCONTRAVE®
March 6, 2023
Currax Files Lawsuit Against Found Health for False Marketing of Generic Equivalent of CONTRAVE®
See moreCURRAX PHARMACEUTICALS
August 30, 2022
One Size Does Not Fit All™: Currax Pharmaceuticals Launches New Campaign to Address Emotional Eating Challenges Faced by Individuals Seeking Weight Loss
See moreCURRAX PHARMACEUTICALS
June 7, 2022